Carlos Barrios
Carlos Barrios is the most visible Latin American voice in global breast cancer trials and a founder of the region's cooperative group LACOG.
Carlos Barrios has been a steering-committee member on numerous global breast cancer trials and co-founded the Latin American Cooperative Oncology Group, expanding trial access across the region; he collaborates with major São Paulo centres.
Patients with hormone-receptor-positive metastatic breast cancer that has stopped responding to endocrine therapy can be offered trastuzumab deruxtecan as their first chemotherapy-type treatment if the tumour shows any HER2 staining, rather than waiting until after conventional chemotherapy. Whether to use it before or after chemotherapy is now a choice, since overall survival was not shown to differ and the drug carries a risk of lung inflammation.
Ribociclib is a second adjuvant CDK4/6 option, and the only one with data in node-negative stage II disease. Roughly 3 in 100 patients avoid a relapse or death at three years, so the decision depends heavily on individual risk, tolerance of a three-year oral drug, and cost. Whether the benefit persists after treatment ends, as it did with abemaciclib, needs longer follow-up.
For hormone-receptor-positive metastatic breast cancer that has already had chemotherapy, Dato-DXd controls the disease for longer with fewer severe side effects than chemotherapy, but does not help patients live longer, so it is not a standard option here. The result is a reminder that progression-free survival is a surrogate; regulators and clinicians should wait for survival data before adopting an ADC in a setting where later therapies are effective.
Pages like this
not linked directly; found by shared links- PersonSeock-Ah Im
Shares NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival, DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, HR-positive / HER2-negative breast cancer.
- PersonSudeep Gupta
Shares Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded, Burden-matched funding for trials led in low- and middle-income countries, HR-positive / HER2-negative breast cancer.
- PersonKan Yonemori
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonBinghe Xu
Shares NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonAndré Ilbawi
Shares Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded, HR-positive / HER2-negative breast cancer.
- PersonJoohyuk Sohn
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonRajendra Badwe
Shares Burden-matched funding for trials led in low- and middle-income countries, HR-positive / HER2-negative breast cancer.
- PersonSara A. Hurvitz
Shares NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.